GLPs
GLP-1 receptor agonists and related compounds for metabolic research

RT10
RT10
Retatrutide is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, demonstrating significant potential in metabolic research for obesity and type 2 diabetes.

RT20
RT20
Retatrutide is an investigational triple-agonist peptide targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, showing significant promise in metabolic research.

RT30
RT30
Retatrutide is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, showing significant promise in metabolic research, particularly for obesity and type 2 diabetes.

TR10
TZ10
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, engineered for its potent effects on glucose homeostasis and metabolic regulation.

TR20
TZ20
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, engineered for its potent effects on glucose homeostasis and metabolic regulation.

TR30
TZ30
Tirzepatide is a novel dual GIP and GLP-1 receptor agonist, representing a significant advancement in metabolic research for its potent effects on glucose homeostasis and weight regulation.
